Abstract
Justification and objectives: oral antineoplastic therapy has advantages compared to other
 therapies for the treatment of cancer, as it is administered at home, in a simple and fast way.
 However, this therapy increases patients’ responsibility for their treatment, and compliance is
 critical to its effectiveness. Few studies are evident regarding pharmacotherapeutic follow-up
 in oral antineoplastic therapy. In this context, this study seeks to assess adherence to tamoxifen
 treatment in women with breast cancer, before and after pharmacotherapeutic follow-up.
 Methods: this is a randomized, quantitative clinical study. Data collection was carried out for
 six months. Random randomization was divided into a control group and a follow-up group,
 with the follow-up subdivided into before and after follow-up. The follow-up group received
 individual pharmaceutical interventions monthly. Adherence was assessed by The Brief
 Medication Questionnaire, Brazilian version and drug-related problems as to necessity,
 effectiveness, and safety. Results: after pharmaceutical follow-p, a difference was observed
 between the follow-up group and the control group regarding physical activity (p=0.043),
 treatment adherence (p=0.006), reduction of side effects (p=0.003) and associated diseases
 (p=0.002). The most frequent drug-related problems were safety and adherence, for which 54
 pharmaceutical interventions were performed. The side effects described by patients mainly
 affected the genital system and gastrointestinal tract. Conclusion: it was evident that
 pharmacotherapeutic follow-up effectively contributed to adherence to treatment with
 tamoxifen and the pharmaceutical interventions performed contributed to prevention and
 reduction of drug-related problems.
Highlights
Cancer is a public health problem, with high incidence and morbidity and mortality, requiring care and consequences for patients and families
Twenty-one women participated in the study, 11 in follow-up group (FG) and 10 in control group (CG)
drug-related problems (DRP): drug-related problem; TMX: tamoxifen. It is evident from the results of the present study that the performance of pharmaceutical care promoted an improvement in adherence to drug treatment with oral antineoplastic agents, since in FG, adherence increased significantly when compared to CG
Summary
Cancer is a public health problem, with high incidence and morbidity and mortality, requiring care and consequences for patients and families. Breast cancer is the most prevalent in Brazil and in the world, with the exception of cases of non-melanoma skin cancer. Breast cancer treatment varies according to the stage of the disease, its biological, clinical and sociodemographic characteristics. Treatment modalities include local treatment such as surgery and radiation therapy, and systemic treatment with chemotherapy, hormone therapy and biological therapy.[2] Oral hormone therapy comprises an important part of treatment associated with increased long-term survival and reduced risk of recurrence and mortality.[2,3] Among the hormonal drugs used in breast cancer, tamoxifen (TMX), a selective estrogen receptor modulator, is the most used.[3,4]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
